ICSI Versus Conventional IVF in Non-male Factor Couples

The Effectiveness of Intracytoplasmic Sperm Injection Versus Conventional in Vitro Fertilization in Couples With Non-male Factor Infertility: a Randomized Controlled Trial

Conventionally, ICSI was initially developed and has been shown to be an effective treatment for male factor infertility. It is increasingly being used for patients without a male factor diagnosis, despite the lack of clinical evidence to support its use. Moreover, ICSI is an invasive and expensive procedure. This multi-center, randomized, controlled, parallel-group trial will be conducted to compare the effectiveness of ICSI versus conventional IVF in infertile couples scheduled for IVF treatment, in whom the male partner has normal sperm.

Study Overview

• Status: Completed
• Conditions: Infertility
• Intervention / Treatment: Procedure: ICSI; Procedure: IVF

Detailed Description

All patients undergoing IVF/ICSI will be treated with a GnRH antagonist protocol. Recombinant FSH (Puregon, MSD) will be given on day 2 or day 3 of menstrual cycle for 5 days. The starting dose is individualized for each patient based on the following criteria: AMH <0.7 ng/mL, dose 300 IU/day; AMH 0.7-2.1 ng/mL, dose 200 IU/day; AMH >2.1 ng/mL, dose 150 IU/day. After that, investigators can titrate the dose based on their clinical judgment. Follicular development will be monitored by ultrasound scanning and measurement of estradiol and progesterone levels, starting on day 5 of stimulation. Scanning and hormonal measurement will be repeated every 2 to 3 days, depending on the size of follicles. An antagonist is routinely used on day 5 until the day of triggering. Criteria for triggering, by hCG (Ovitrelle 250 mg, Merck, Germany) will be the presence of at least three leading follicles of 17 mm. In women with excessive follicular response (≥15 follicles ≥12 mm), 0,2 mg Triptorelin (Diphereline, Ipsen Beaufour, France) will be used when there are at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.

Randomization and allocation of participants to study groups will be performed on the day of egg pick up, after having obtained the semen from the husband. Eligible participants that have provided informed consent will be randomised to either ICSI or conventional IVF.

In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.

In conventional IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.

In both groups, fertilization check will be performed under inverted microscope at period of 16-18 hours after insemination. On day 3, embryo evaluation will be performed at fixed time point 66±2 hours after fertilization, using the Istanbul consensus. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen. Luteal-phase support will be done with estradiol (Valiera 2mg) 8mg/day and vaginal progesterone 800mg/day (Cyclogest 400mg) until 7th week of gestation.

If there are contra-indications for fresh embryo transfer, a freeze-all strategy will be applied, using Cryotech technique. Indications for freeze-all include: risk of ovarian hyperstimulation syndrome (OHSS), premature progesterone rise (≥1.5 ng/ml), thin endometrium (<7 mm), fluid in cavity on day of embryo transfer, endometrial polyp, hydrosalpinx that have not removed before oocyte retrieval.

In the next cycle, endometrium will be prepared by using estradiol (Valiera 2 mg, 8 mg/day) orally, starting from day 2-3 of menstrual cycle. When the endometrium thickness reaches 8 mm or more, patients will start using progesterone vaginally (Cyclogest 400 mg, 800 mg/day). Embryo transfer will be performed 3 days after using progesterone. On the day of embryo transfer, embryos will be thawed. In the frozen/thawed cycle, the best embryos will be utilized first, as in fresh transfer. Two hours after thawing, a maximum of 2 surviving embryos will be transferred into the uterus under ultrasound guidance. Luteal phase support will be provided with estradiol (Valiera 2mg) 8mg/day and vaginal progesterone 800 mg/day (Cyclogest 400 mg) until the seventh week of gestation.

In both groups, clinicians who perform embryo transfer, either fresh or frozen cycles, will be blinded to the intervention.

A serum hCG will be measured 2 weeks after embryo transferred, and if positive, an ultrasound scan of the uterus will be performed at gestational weeks 7 and 12. At 11 - 12 weeks of gestation, participants will be referred to the Outpatient clininc, O&G Department, My Duc hospital or An Sinh hospital for prenatal care until giving birth.

• Study Type: Interventional
• Enrollment (Actual): 1064
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Vietnam
  • Hochiminh city, Vietnam
    • Dang Q Vinh

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Having ≤ 2 IVF/ICSI cycles
• Total sperm count and motility are normal (WHO, 2010)
• Antagonist protocol
• Agree to have ≤ 2 embryos transferred
• Not participating in another IVF study at the same time

Exclusion Criteria:

• In-vitro maturation (IVM) cycles
• Using frozen semen
• Poor fertilization in previous cycle (≤ 25%)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Intracytoplasmic Sperm Injection (ICSI); All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering. Insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated. Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen.	Procedure: ICSI; In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
ACTIVE_COMPARATOR: In Vitro Fertilization (IVF); All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering. Insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours (100,000 motile sperm/ml). Inseminated OCCs will be cultured overnight in culture medium. Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3. A maximum of 2 embryos will be transferred. The remaining grade 1-2 embryos will be frozen.	Procedure: IVF; In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ongoing pregnancy resulting in live birth after the first embryo transfer of the started treatment cycle.	Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count). For the timing of this occur, ongoing pregnancy will be used, conditional on the fact that this ongoing pregnancy results in live birth.	At 12 weeks of gestation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cost-effectiveness	Including direct and indirect costs; costs related to complications treatment. Cost data will be collected for a supplementary analysis and will be reported in a separated paper.	Two year after randomization
Ongoing pregnancy	Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer	At 12 weeks' gestation
Fertilization rate per oocyte inseminated/injected	Fertilization is defined as the appearance of 2 PN	At 16-18 hours after injected or 17-19 hours after inseminated
Fertilization rate per oocyte retrieved	Fertilization is defined as the appearance of 2 PN	At 16-18 hours after injected or 17-19 hours after inseminated
Abnormal fertilization rate	Abnormal fertilization is defined as the appearance of 1PN or ≥3 PN	At 16-18 hours after injected or 17-19 hours after inseminated
Total fertilization failure rate	Total fertilization is defined as the absence of any zygotes with 2PN	At 16-18 hours after injected or 17-19 hours after inseminated
Number of embryos on day 3	Number of embryos on day 3	3 days after oocytes pick-up day in IVF/ICSI
Number of good quality embryo on day 3	Numbers of embryos on day 3 with good quality	3 days after oocytes pick-up day in IVF/ICSI
Number of embryo freezing on day 3	Number of embryos freezing on day 3	3 days after oocytes pick-up day in IVF/ICSI
Positive pregnancy test	Positive pregnancy test is defined as a serum human chorionic gonadotropin level greater than 25 mIU/mL after the completion of the first transfer	14 days after embryo transfer
Clinical pregnancy	Clinical pregnancy is defined as the presence of at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity, after the completion of the first transfer	At 7 weeks' gestation
Implantation rate	Implantation rate is defined as the number of gestational sacs per number of embryos transferred after the completion of the first transfer	At 3 weeks after embryo transferred
Cumulative ongoing pregnancy	Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after transfer of all embryos from the started treatment cycle.	At 12 weeks' gestation at 12 months after randomization. After 12 months, most patients doing IVF have finished all their frozen embryos; therefore, we consider this time point for analyzing the cumulative ongoing pregnancy rate.
Ongoing pregnancy resulting in live birth obtained from all embryos from the first started treatment cycle	Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count).	12 weeks of gestation at 12 months after randomization
Time from randomization to ongoing pregnancy	Time from randomization to ongoing pregnancy after the completion of the first transfer	12 weeks of gestation after the completion of first transfer
Ovarian hyperstimulation syndrome (OHSS)	Symptoms of OHSS	At 10 days after hCG injection and 14 days after embryo transfer
Ectopic pregnancy	A pregnancy in which implantation takes place outside the uterine cavity after completion of the first transfer	At 12 weeks of gestation after the completion of the first transfer
Ectopic pregnancy	A pregnancy in which implantation takes place outside the uterine cavity after transfer of all embryos from the started treatment cycle.	At 12 weeks of gestation at 12 months after randomization.
Miscarriage	The loss of a clinical pregnancy at 24 weeks of gestation after the completion of the first transfer	At 24 weeks of gestation after the completion of the first transfer
Miscarriage	The loss of a clinical pregnancy at 24 weeks of gestation after the completion transfer of all embryos from the started treatment cycle	At 24 weeks of gestation at 12 months after the randomization.
Multiple pregnancy	Multiple pregnancy is explained as two or more gestational sacs or positive heart beats by transvaginal sonography, after the completion of the first transfer	7 weeks' gestation after the completion of the first transfer
Multiple pregnancy	Multiple pregnancy is explained as two or more gestational sacs or positive heart beats by transvaginal sonography, after the completion transfer of all embryos from the started treatment cycle	7 weeks' gestation at 12 months after randomization
Multiple delivery	Multiple delivery is defined as birth of more than one baby beyond 24 weeks, after the completion of the first transfer	At birth, after the completion of the first transfer
Multiple delivery	Multiple delivery is defined as birth of more than one baby beyond 24 weeks, after the completion transfer of all embryos from the started treatment cycle	At birth at 12 months after randomization
Gestational diabetes mellitus	Development of diabetes during pregnancy	At 24 weeks of gestation after the completion of the first transfer
Gestational diabetes mellitus	Development of diabetes during pregnancy	At 24 weeks of gestation at 12 months after randomization
Hypertensive disorders of pregnancy	Hypertensive disorders of pregnancy will include pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia)	From 20 weeks of gestation up to at birth after the completion of the first transfer
Hypertensive disorders of pregnancy	Hypertensive disorders of pregnancy will include pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia)	From 20 weeks of gestation up to at birth at 12 months after randomization
Antepartum haemorrhage	Including placenta previa, placenta accreta and unexplained	From 20 weeks of gestation up to at birth, after the completion of the first transfer
Antepartum haemorrhage	Including placenta previa, placenta accreta and unexplained	From 20 weeks of gestation up to at birth, at 12 months after randomization
Gestational age at delivery	Gestational age at delivery	At birth, after the completion of the first transfer
Gestational age at delivery	Gestational age at delivery	At birth, at 12 months after randomization
Preterm delivery	Preterm delivery is defined as any delivery at <24, <28, <32, <37 completed weeks' gestation	At birth, after the completion of the first transfer
Preterm delivery	Preterm delivery is defined as any delivery at <24, <28, <32, <37 completed weeks' gestation	At birth, at 12 months after randomization
Spontaneous preterm birth	Spontaneous preterm birth is defined as delivery spontaneously at <24, <28, <32, <37 completed weeks	At birth, after the completion of the first transfer
Spontaneous preterm birth	Spontaneous preterm birth is defined as delivery spontaneously at <24, <28, <32, <37 completed weeks	At birth, at 12 months after randomization
Iatrogenic preterm birth	Iatrogenic preterm birth is defined as delivery non-spontaneously at <24, <28, <32, <37 completed weeks	At birth, after the completion of the first transfer
Iatrogenic preterm birth	Iatrogenic preterm birth is defined as delivery non-spontaneously at <24, <28, <32, <37 completed weeks	At birth, at 12 months after randomization
Birth weight	Weight of newborn	At birth, after the completion of the first transfer
Birth weight	Weight of newborn	At birth, at 12 months after randomization
Low birth weight	Low birth weight is defined as <2500 gm	At birth, after the completion of the first transfer
Low birth weight	Low birth weight is defined as <2500 gm	At birth, at 12 months after randomization
Very low birth weight	Very low birth weight is defined as <1500 gm	At birth, after the completion of the first transfer
Very low birth weight	Very low birth weight is defined as <1500 gm	At birth, at 12 months after randomization
High birth weight	High birth weight is defined as >4000 gm	At birth, after the completion of the first transfer
High birth weight	High birth weight is defined as >4000 gm	At birth, at 12 months after randomization
Very high birth weight	Very high birth weight is defined as >4500 gm	At birth, after the completion of the first transfer
Very high birth weight	Very high birth weight is defined as >4500 gm	At birth, at 12 months after randomization
Large for gestational age	Large for gestational age is defined as birth weight >90th percentile	At birth, after the completion of the first transfer
Large for gestational age	Large for gestational age is defined as birth weight >90th percentile	At birth, at 12 months after randomization
Small for gestational age	Small for gestational age is defined as birth weight <10th percentile	At birth, after the completion of the first transfer
Small for gestational age	Small for gestational age is defined as birth weight <10th percentile	At birth, at 12 months after randomization
Congenital anomaly diagnosed at birth	Any congenital anomaly will be included	At birth, after the completion of the first transfer
Congenital anomaly diagnosed at birth	Any congenital anomaly will be included	At birth, at 12 months after randomization
Admission to NICU	The admittance of the newborn to NICU	7 days after delivery after the completion of the first transfer
Admission to NICU	The admittance of the newborn to NICU	7 days after delivery, at 12 months after randomization
Genetic and epigenetic analysis of newborn	Maternal whole blood; newborn's materials including cord blood, neonatal buccal smear, and placental tissue will be collected. Data will be collected for a supplementary analysis and will be reported in a separated paper.	1 day (Prior to the initiation of IVF/IVM) and 1 day ( at the time of delivery)

Collaborators and Investigators

• Sponsor: Mỹ Đức Hospital
• Collaborators: An Sinh Hospital
• Investigators: Principal Investigator: Lan N Vuong, PhD, University of Medicine and Pharmacy at Ho Chi Minh City

Publications and helpful links

General Publications

• Dang VQ, Vuong LN, Luu TM, Pham TD, Ho TM, Ha AN, Truong BT, Phan AK, Nguyen DP, Pham TN, Pham QT, Wang R, Norman RJ, Mol BW. Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial. Lancet. 2021 Apr 24;397(10284):1554-1563. doi: 10.1016/S0140-6736(21)00535-3.
• Dang VQ, Vuong LN, Ho TM, Ha AN, Nguyen QN, Truong BT, Pham QT, Wang R, Norman RJ, Mol BW. The effectiveness of ICSI versus conventional IVF in couples with non-male factor infertility: study protocol for a randomised controlled trial. Hum Reprod Open. 2019 Mar 27;2019(2):hoz006. doi: 10.1093/hropen/hoz006. eCollection 2019.

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 16, 2018
• Primary Completion (ACTUAL): August 1, 2020
• Study Completion (ACTUAL): August 12, 2020

Study Registration Dates

• First Submitted: February 2, 2018
• First Submitted That Met QC Criteria: February 8, 2018
• First Posted (ACTUAL): February 12, 2018

Study Record Updates

• Last Update Posted (ACTUAL): October 9, 2020
• Last Update Submitted That Met QC Criteria: October 7, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: ICSI; Conventional IVF; Non-male factor
• Additional Relevant MeSH Terms: Infertility
• Other Study ID Numbers: CS/MD/17/12; CS/AS/17/10 (OTHER: An Sinh Hospital)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No